The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial
Michael Berk, Olivia Dean, Sue M Cotton, Clarissa S Gama, Flavio Kapczinski, Brisa S Fernandes, Kristy Kohlmann, Susan Jeavons, Karen Hewitt, Christine Allwang, Heidi Cobb, Ashley I Bush, Ian Schapkaitz, Seetal Dodd, Gin S Malhi
Journal of Affective Disorders | ELSEVIER SCIENCE BV | Published : 2011
Awarded by Stanley Medical Research Institute
Awarded by NHMRC
This study received funding from grant 06TGF-996 from the Stanley Medical Research Institute for the expenses of the trial. Heidi Cobb benefited from support from NHMRC Program Grant ID 510135. The funding sources had no role in study design, management, data analysis or manuscript preparation.Berk and Bush are co-inventors on two provisional patents regarding the use of NAC and related compounds for psychiatric indications, which, whilst assigned to the Mental Health Research Institute, could lead to personal remuneration upon a commercialisation event. Bush is a stock shareholder of Eucalyptus Biosciences and Prams Biotechnologies. Berk has served on advisory boards and received funds and/or honoraria from Astra Zeneca, Eli Lilly, Janssen Cilag, Lundbeck, Servier, Glaxo Smith Kline, Organon, Novartis, Pfizer, Bristol Myers Squibb, Sanofi Synthelabo and Solvay. Malhi has served on advisory boards and received funds and/or honoraria from Astra Zeneca. Eli Lilly, Janssen Cilag, Lundbeck, Servier, Pfizer, Organon and Wyeth. Dodd has received funds and honoraria from Servier and Eli Lilly All other authors declare that they have no conflicts of interest.